IOVA EBITDA | IOVANCE BIOTHERAPEUTICS, INC.

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) EBITDA

2026-06-30: Basis Reported; EBITDA -$48.12M*; Operating income -$51.91M; Depreciation and amortization $3.78M*.
2026-03-31: Basis Reported; EBITDA -$78.22M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA -$69.74M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA -$91.71M*; Operating income -$94.90M; Depreciation and amortization $3.19M*.

Complete source-backed ebitda history.

Available history: 2017-12-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$48.12M*	-$51.91M	$3.78M*	$99.31M	-48.45%*	$5.44M*	-$60.84M*	(m)	$58.85M	(m)	-$1.37M
2026-03-31	Reported	-$78.22M	(m)	(m)	(m)	-109.51%	$6.61M	-$72.07M	(m)	$62.49M	(m)	-$665.00K
2025-12-31	Reported	-$69.74M	(m)	(m)	(m)	-80.37%	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	-$91.71M*	-$94.90M	$3.19M*	$67.45M	-135.96%*	$10.84M*	-$78.70M*	(m)	$75.17M	(m)	-$2.40M
2025-06-30	Reported	-$110.37M	(m)	(m)	(m)	-184.10%	$7.46M*	-$67.45M*	(m)	$77.93M	(m)	$1.99M
2025-03-31	Reported	-$118.65M	(m)	(m)	(m)	-240.55%	$6.21M	-$103.69M	(m)	$75.97M	(m)	-$1.84M
2024-12-31	Reported	-$83.3M	(m)	(m)	(m)	-113.04%	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$86.07M	(m)	(m)	(m)	-146.98%	$2.29M*	-$58.97M*	(m)	$67.04M	(m)	-$1.52M
2024-06-30	Reported	-$98.91M	(m)	(m)	(m)	-317.99%	$442.00K*	-$98.43M*	(m)	$62.08M	(m)	-$1.46M
2024-03-31	Reported	-$114.74M	(m)	(m)	(m)	-16048.11%	$4.17M	-$122.28M	(m)	$79.78M	(m)	-$1.41M
2023-12-31	Reported	-$118.31M	(m)	(m)	(m)	-24545.02%	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$115.46M	(m)	(m)	(m)	-24618.55%	$3.58M*	-$84.08M*	(m)	$87.53M	(m)	-$1.24M
2023-06-30	Reported	-$107.19M	(m)	(m)	(m)	-45036.13%	$9.52M*	-$93.95M*	(m)	$86.35M	(m)	-$477.00K
2023-03-31	Reported	-$108.09M	(m)	(m)	(m)	(m)	$5.66M	-$99.81M	(m)	$82.73M	(m)	$0.00
2022-12-31	Reported	-$104.22M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$97.9M	(m)	(m)	(m)	(m)	$1.39M*	-$63.65M*	(m)	$72.50M	(m)	(m)
2022-06-30	Reported	-$97.53M	(m)	(m)	(m)	(m)	$4.58M*	-$77.64M*	(m)	$73.41M	(m)	(m)
2022-03-31	Reported	-$89.92M	(m)	(m)	(m)	(m)	$11.44M	-$73.80M	(m)	$68.30M	(m)	(m)
2021-12-31	Reported	-$98.12M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$85.21M*	-$86.24M	$1.03M*	(m)	(m)	$9.69M*	-$57.69M*	(m)	$65.36M	(m)	(m)
2021-06-30	Reported	-$81.06M*	-$81.43M	$366.00K*	(m)	(m)	$9.62M*	-$54.01M*	(m)	$62.12M	(m)	(m)
2021-03-31	Reported	-$75.2M	(m)	(m)	(m)	(m)	$10.71M	-$62.39M	(m)	$55.95M	(m)	(m)
2020-12-31	Reported	-$68.21M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$58.66M*	-$58.97M	$307.00K*	(m)	(m)	$17.84M*	-$40.52M*	(m)	$43.05M	(m)	(m)
2020-06-30	Reported	-$63.37M*	-$63.63M	$260.00K*	(m)	(m)	$4.97M*	-$36.63M*	(m)	$49.27M	(m)	(m)
2020-03-31	Reported	-$70.56M	(m)	(m)	(m)	(m)	$637.00K	-$65.29M	(m)	$56.95M	(m)	(m)
2019-12-31	Reported	-$64.82M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$51.30M*	-$51.61M	$315.00K*	(m)	(m)	$1.23M*	-$42.18M*	(m)	$41.58M	(m)	(m)
2019-06-30	Reported	-$49.88M*	-$50.16M	$289.00K*	(m)	(m)	$1.43M*	-$33.80M*	(m)	$39.30M	(m)	(m)
2019-03-31	Reported	-$39.72M	(m)	(m)	(m)	(m)	$824.00K	-$29.09M	(m)	$30.91M	(m)	(m)
2018-12-31	Reported	-$34.69M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$34.81M*	-$35.06M	$251.00K*	(m)	(m)	$463.00K*	-$27.93M*	(m)	$27.95M	(m)	(m)
2018-06-30	Reported	(m)	-$31.38M	(m)	(m)	(m)	$418.00K*	-$23.92M*	(m)	$24.55M	(m)	(m)
2018-03-31	Reported	(m)	-$26.88M	(m)	(m)	(m)	$22.00K	-$17.85M	(m)	$19.91M	(m)	(m)
2017-09-30	Reported	(m)	-$22.34M	(m)	(m)	(m)	$263.00K*	-$21.45M*	(m)	$16.68M	(m)	(m)
2017-06-30	Reported	(m)	-$23.58M	(m)	(m)	(m)	$25.00K*	-$17.50M*	(m)	$18.65M	(m)	(m)
2017-03-31	Reported	(m)	-$20.88M	(m)	(m)	(m)	$798.00K	-$18.80M	(m)	$15.59M	(m)	(m)
2016-09-30	Reported	(m)	-$18.98M	(m)	(m)	(m)	$725.00K*	(m)	(m)	$8.48M	(m)	(m)
2016-06-30	Reported	(m)	-$11.73M	(m)	(m)	(m)	$54.00K*	(m)	(m)	$4.46M	(m)	(m)
2016-03-31	Reported	(m)	-$7.01M	(m)	(m)	(m)	$2.00K	(m)	(m)	$4.19M	(m)	(m)
2015-09-30	Reported	(m)	-$7.64M	(m)	(m)	(m)	$73.00K*	(m)	(m)	$4.96M	(m)	(m)
2015-06-30	Reported	(m)	-$6.44M	(m)	(m)	(m)	$137.00K*	(m)	(m)	$4.05M	(m)	(m)
2015-03-31	Reported	(m)	-$5.30M	(m)	(m)	(m)	$782.00K	$3.46M	(m)	$2.40M	(m)	(m)
2014-09-30	Reported	(m)	-$2.80M	(m)	(m)	(m)	$161.26K*	-$1.73M*	(m)	$354.00K	(m)	(m)
2014-06-30	Reported	(m)	-$2.11M	(m)	(m)	(m)	$2.31K*	-$1.32M*	(m)	$493.99K	(m)	(m)
2014-03-31	Reported	(m)	-$2.26M	(m)	(m)	(m)	$3.44K	-$2.27M	(m)	$302.66K	(m)	(m)
2013-09-30	Reported	(m)	-$9.41M	(m)	(m)	(m)	$12.70K*	-$427.07K*	(m)	$250.00K	(m)	(m)
2013-06-30	Reported	(m)	-$1.03M	(m)	(m)	(m)	$0.00*	-$681.93K*	(m)	$250.00K	(m)	(m)
2013-03-31	Reported	(m)	-$704.91K	(m)	(m)	(m)	$0.00	-$300.00K	(m)	$270.00K	(m)	(m)
2012-09-30	Reported	(m)	-$1.63M	(m)	(m)	(m)	(m)	-$280.74K*	(m)	$250.00K	(m)	(m)
2012-06-30	Reported	(m)	-$1.65M	(m)	(m)	(m)	(m)	-$1.20M*	(m)	$270.00K	(m)	(m)
2012-03-31	Reported	(m)	-$3.14M	(m)	(m)	(m)	$0.00	-$760.22K	(m)	$886.00K	(m)	(m)
2011-09-30	Reported	(m)	-$5.81M	(m)	(m)	(m)	$3.46K*	-$1.65M*	(m)	$0.00	(m)	(m)
2011-06-30	Reported	(m)	-$10.56M	(m)	(m)	(m)	$16.86K*	-$1.27M*	(m)	(m)	(m)	(m)
2011-03-31	Reported	(m)	-$658.25K	(m)	(m)	(m)	$0.00	-$564.48K	(m)	$0.00	(m)	(m)
2010-09-30	Reported	(m)	-$167.03K	(m)	(m)	(m)	$0.00*	-$113.32K*	(m)	(m)	(m)	(m)
2010-06-30	Reported	(m)	-$84.63K	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$390.49M	(m)	(m)	(m)	-148.19%	$33.84M	-$302.41M	(m)	$300.27M	(m)	-$2.07M
2024-12-31	Reported	-$384.02M	(m)	(m)	(m)	-234.06%	$11.07M	-$352.98M	(m)	$276.23M	(m)	-$2.83M
2023-12-31	Reported	-$448.99M	(m)	(m)	(m)	-37762.07%	$22.29M	-$361.82M	(m)	$333.19M	(m)	-$3.48M
2022-12-31	Reported	-$389.57M	(m)	(m)	(m)	(m)	$20.43M	-$292.76M	(m)	$294.78M	(m)	$0.00
2021-12-31	Reported	-$339.59M	(m)	(m)	(m)	(m)	$37.57M	-$227.94M	(m)	$259.04M	(m)	$0.00
2020-12-31	Reported	-$260.8M	(m)	(m)	(m)	(m)	$46.79M	-$205.13M	(m)	$201.73M	(m)	$0.00
2019-12-31	Reported	-$205.7M	(m)	(m)	(m)	(m)	$6.92M	-$158.89M	(m)	$166.02M	(m)	$0.00
2018-12-31	Reported	-$127.3M	(m)	(m)	(m)	(m)	$1.20M	-$101.25M	(m)	$99.83M	(m)	$0.00
2017-12-31	Reported	-$91.93M	(m)	(m)	(m)	(m)	$1.03M	-$78.71M	(m)	$71.61M	(m)	$0.00
2016-12-31	Reported	(m)	-$53.64M	(m)	(m)	(m)	$1.52M	-$32.67M	(m)	$26.94M	(m)	$0.00
2015-12-31	Reported	(m)	-$27.86M	(m)	(m)	(m)	$1.14M	-$18.38M	(m)	$15.47M	(m)	$0.00
2014-12-31	Reported	(m)	-$12.04M	(m)	(m)	(m)	$1.59M	$8.63M	(m)	$3.85M	(m)	$0.00
2013-12-31	Reported	(m)	-$22.64M	(m)	(m)	(m)	$13.00K	-$3.66M	(m)	$2.15M	(m)	(m)
2012-12-31	Reported	(m)	-$8.13M	(m)	(m)	(m)	$0.00	-$2.24M	(m)	$1.66M	(m)	(m)
2011-12-31	Reported	(m)	-$21.22M	(m)	(m)	(m)	$31.05K	-$6.19M	(m)	$1.76M	(m)	(m)
2010-12-31	Reported	(m)	-$815.41K	(m)	(m)	(m)	$0.00	-$620.80K	(m)	$171.48K	(m)	(m)
2009-12-31	Reported	(m)	-$15.77K	(m)	(m)	(m)	$0.00	-$14.45K	(m)	$0.00	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Adaptive Biotechnologies Corp (ADPT)	United States	$4.719B	-53.43
CRISPR Therapeutics AG (CRSP)		$5.390B	-11.68
Relay Therapeutics, Inc. (RLAY)	United States	$3.884B	-14.30
Scholar Rock Holding Corp (SRRK)	United States	$5.920B	-16.37
CG Oncology, Inc. (CGON)	United States	$6.095B	-27.95
Tarsus Pharmaceuticals, Inc. (TARS)	United States	$3.329B	-58.60
Denali Therapeutics Inc. (DNLI)	United States	$3.274B	-8.04
Immunovant, Inc. (IMVT)	United States	$7.028B	-14.78
Beam Therapeutics Inc. (BEAM)	United States	$2.549B	-41.51
Greenland Mines Ltd (GRML)	United States	$2.362B